Upgrade to SI Premium - Free Trial

After-Hours Stock Movers 01/05: (CNAT) (ICON) (BLUE) Higher; (EPZM) (CEMP) (OTIC) Lower (more...)

January 5, 2016 6:12 PM
Conatus Pharmaceuticals (NASDAQ: CNAT) 15% HIGHER; three-month, double-blind, placebo-controlled stage of the company’s multicenter Phase 2 Liver Cirrhosis clinical trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Special Reports

Next Articles